Immix Biopharma (NASDAQ:IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy. AL amyloidos
Detailed price information for Immix Biopharma Inc (IMMX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.
Immix Biopharma (IMMX) closed its previously announced underwritten offering of 11.4 million common
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after ded
I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Immix Biopharma (IMMX).
ROSA and the RIO Platform Integration with Immix Now Available for Use, with the Nation's Largest Guarding and Monitoring Companies EngagedDetroit, Michigan--(Newsfile Corp. - September 14, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX), today announced that the integration of its subsidiary, Robotic Assistance Devices, Inc. (RAD), with the Immix® platform is now available to Immix users, supporting RAD's ROSA™ and RIO™ platforms. The move to full release follows the...
Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.